Trial reportJournal for immunotherapy of cancer2019
Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis.
Trial report in Journal for immunotherapy of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02859454 (A Phase II Study of Avelumab in Subjects With Recurrent Respiratory Papillomatosis), which is not on this map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of Avelumab in Subjects With Recurrent Respiratory Papillomatosis
Who cites it
33 citing papers in PubMed, 54 citations in OpenAlex.
- PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial.The Lancet. Respiratory medicine · 2025Trial
- Outcomes After Human Papillomavirus Vaccination in Patients With Recurrent Respiratory Papillomatosis: A Nonrandomized Clinical Trial.JAMA otolaryngology-- head & neck surgery · 2022Trial
- Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis.Journal for immunotherapy of cancer · 2021Trial
- Recurrent Respiratory Papillomatosis Foundation Position Statement on the Management of Adults With RRP.The Laryngoscope · 2026Article
- Preclinical efficacy of dendritic cells loaded with newly identified HPV11 E6-derived CD8NPJ vaccines · 2026Article
- Recurrent respiratory papillomatosis: is patient well-being related to anatomical manifestation?European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Zopapogene Imadenovec: First Approval.Molecular diagnosis & therapy · 2026Review
- Major Human Leukocyte Antigen Expression in Respiratory Papillomatosis Clinical Specimens.The Laryngoscope · 2025Article
- Article
- Unexpected Severe Tracheal Papilloma During Induction.Clinical case reports · 2025Article
- Laryngeal Papillomatosis.Cancers · 2025Review
- Quantification and Functional Studies of Neutrophilic Cells Identifies Distinct Papilloma Phenotypes.The Laryngoscope · 2024Article
- Profiling of VEGF Receptors and Immune Checkpoints in Recurrent Respiratory Papillomatosis.The Laryngoscope · 2024Article
- Pulmonary Involvement in Recurrent Respiratory Papillomatosis: A Systematic Review.Infectious disease reports · 2024Review
- The tumor microenvironment state associates with response to HPV therapeutic vaccination in patients with respiratory papillomatosis.Science translational medicine · 2023Article
- Association between human papillomavirus particle production and the severity of recurrent respiratory papillomatosis.Scientific reports · 2023Article
- Systemic bevacizumab for pediatric patients with aggressive recurrent respiratory papillomatosis: One single-center experience of eight patients.Laryngoscope investigative otolaryngology · 2023Article
- [Recurrent laryngeal papillomatosis].HNO · 2023Review
- Current Infections of the Orofacial Region: Treatment, Diagnosis, and Epidemiology.Life (Basel, Switzerland) · 2023Review
- Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022.Children (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 3 countries.
Funding
Abstract
backgroundRecurrent respiratory papillomatosis (RRP) is a human papillomavirus (HPV)-driven disorder that causes substantial morbidity and can lead to fatal distal airway obstruction and post-obstructive pneumonias. Patients require frequent surgical debridement of disease, and no approved systemic adjuvant therapies exist.
methodsA phase II study was conducted to investigate the clinical activity and safety of programmed death-ligand 1 (PD-L1) blockade with avelumab in patients with RRP.
resultsTwelve patients were treated. All patients with laryngeal RRP displayed improvement in disease burden, and 5 of 9 (56%) displayed partial responses. None of 4 patients with pulmonary RRP displayed a response. Using each patient's surgical history as their own control, patients required fewer surgical interventions after avelumab treatment (p = 0.008). A subset of partial responders developed HPV-specific reactivity in papilloma-infiltrating T-cells that correlated with reduced HPV viral load and an increased Tissue Inflammation Signature.
conclusionsAvelumab demonstrated safety and clinical activity in patients with laryngeal RRP. Further study of immune checkpoint blockade for RRP, possibly with longer treatment duration or in combination with other immunotherapies aimed at activating antiviral immunity, is warranted.
trial registrationNCT, number NCT02859454 , registered August 9, 2016.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.